Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Synaffix
Synaffix
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Graphs and graph data science in drug discovery
Life sciences data expert Dr Alexander Jarasch discusses what work being done at the Institut de Recherches Servier can teach us about using modern data technologies for early...
Why smaller CDMOs should enhance their operational efficiency now: a CPHI expert guide
CPHI experts advise smaller CDMO's to invest in supply chain resilience, friend shoring and AI to keep up with the predicted uptick in funding for 2025
CPI collaborates with industry leaders to expedite drug manufacturing via digitisation
Digitising manufacturing technologies could allow enhanced ability to scale production, reduce costs and expedite the process
Janssen to adopt Johnson & Johnson brand as the company celebrates 100 years of UK operation
The company's pharmaceutical and medical technology segments will combine under the Johnson & Johnson brand name in the UK
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Innovent Biologics and Synaffix expand ADC collaboration
New deal builds on encouraging preliminary clinical data from the Phase I study of the first antibody-drug conjugate (ADC) developed under the agreement signed in June 2021
Drug Delivery
Lonza to acquire Synaffix and strengthen ADCs offering
The companies will continue to expand their "Centre of Excellence" for bioconjugate technology development, with a focus on out-licensing bioconjugates technologies
Regulatory
Synaffix expands licensing agreement with MacroGenics
The expansion comes just a year after the original February 2022 deal, increasing the total potential consideration by up to $2.2 billion
Distribution
Synaffix announces licensing agreement with CKD Pharm
Under the terms of the agreement, Synaffix has received an upfront payment and is eligible to receive further milestone payments
Drug Delivery
Synaffix enters ADCs agreement with Amgen
Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments
Digital
Synaffix wins ‘Best ADC Platform Technology’ at World ADC Awards
This marks the second time that Synaffix’s ADC platform technology has been acknowledged as industry leading
Research & Development
Synaffix strikes ADC deal with MacroGenics
Under the agreement, Synaffix will be eligible to receive up to $586m in payments
Subscribe now